Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 5/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863979 | 0.88 | MEN1 (0.51) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL31083912 | 0.87 | MEN1 (0.42) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL26774830 | 0.86 | DPP7 (0.49) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL30456801 | 0.86 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL25365117 | 0.86 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL25365110 | 0.86 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL25365122 | 0.86 | MEN1 (0.48) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL30366481 | 0.85 | MEN1 (0.49) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL30448973 | 0.85 | MEN1 (0.46) | MEN1KMT2ADPP7CTSCPRCP | |
| SCHEMBL27212749 | 0.85 | MEN1 (0.46) | MEN1KMT2ADPP7CTSCPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | VIPR2, NPY2R, NPY5R | MEN1 677/4885KMT2A 1907/4885DPP7 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.